Skip to main content
SpringerLink
Log in

Hemorrhage Risks, Patient Perspectives, and Quality-of-Life Issues

  • Chapter
  • First Online:
Handbook of Oral Anticoagulation

  • 1316 Accesses

Abstract

Warfarin is a widely used medication, which is often prescribed to high risk patients with multiple comorbidities who are receiving multiple medications and thus poses a risk of side-effects related to its pharmacologic properties and drug interactions. It is estimated that, in the UK, for example, 950,000 patients are currently taking warfarin (2 % of the general practice population).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modeling. Health Technol Assess. 2007;11:iii-iv, ix-66.

    Google Scholar 

  2. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

    Google Scholar 

  3. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE -LY ) trial. Circulation. 2011;123:2363-2372.

    Google Scholar 

  4. Patel MR, Mahaffey KW , Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.

    Google Scholar 

  5. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-2394.

    Google Scholar 

  6. Granger CB , Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.

    Google Scholar 

  7. Connolly SJ, Eikelboom J, Joyner C, et al; AVE RROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.

    Google Scholar 

  8. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial haemorrhages. Am J Med. 2007;120:700-705.

    Google Scholar 

  9. Connolly SJ, Pogue J, Eikelboom J, et al; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.

    Google Scholar 

  10. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588-1593.

    Google Scholar 

  11. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6:981-993.

    Google Scholar 

  12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.

    Google Scholar 

  13. Mant J, Hobbs FD, Fletcher K, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.

    Google Scholar 

  14. Poli D, Antonucci E, Marcucci R, et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res. 2007;121:347-352.

    Google Scholar 

  15. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.

    Google Scholar 

  16. Kuijer PMM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457-460.

    Google Scholar 

  17. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390-1396.

    Google Scholar 

  18. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting haemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-719.

    Google Scholar 

  19. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.

    Google Scholar 

  20. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol. 2011;58:395-401.

    Google Scholar 

  21. Tay KH, Lane DA, Lip GY. Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin? Thromb Haemost. 2008;100:955-957.

    Google Scholar 

  22. Nieuwlaat R, Capucci A, Lip GY, et al; Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018-3026.

    Google Scholar 

  23. Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke. 2008;39:7-9.

    Google Scholar 

  24. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41-46.

    Google Scholar 

  25. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke. 2008;39:227-230.

    Google Scholar 

  26. Choudhry NK, Anderson GM, Laupacis A, et al. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ. 2006;332:141-145.

    Google Scholar 

  27. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323:1218-1222.

    Google Scholar 

  28. Lip GY , Agnelli G, Thach AA, et al. Oral anticoagulation in atrial fibrillation: a pan-European patient survey. Eur J Intern Med. 2007;18:202-208.

    Google Scholar 

  29. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320:1380-1384.

    Google Scholar 

  30. Lane D, Lip GY. Anti-thrombotic therapy for atrial fibrillation and patients’ preferences for treatment. Age Ageing. 2005;34:1-3.

    Google Scholar 

  31. Lane DA, Ponsford J, Shelley A, et al. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006;110:354-358.

    Google Scholar 

  32. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448.e1-19.

    Google Scholar 

  33. Hagens VE, Ranchor AV, Van Sonderen E, et al; RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43:241-247.

    Google Scholar 

  34. Jenkins LS, Brodsky M, Schron E, et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:112-120.

    Google Scholar 

  35. Das AK, Willcoxson PD , Corrado OJ, West RM. The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation. Age Ageing. 2007;36:95-97.

    Google Scholar 

  36. Lancaster TR, Singer DE, Sheehan MA, et al. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med. 1991;151:1944-1949.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Specialist Registrar in Cardiology, West Midlands Deanery, West Midlands, UK

    Kok-Hoon Tay

  2. University of Birmingham, Birmingham, UK

    Stavros Apostolakis, Deirdre A Lane & Gregory YH Lip

Authors
  1. Kok-Hoon Tay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stavros Apostolakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deirdre A Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory YH Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Birmingham, Birmingham B18 7QH, United Kingdom

    Gregory YH Lip

  2. Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom

    Eduard Shantsila

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Tay, KH., Apostolakis, S., Lane, D.A., Lip, G.Y. (2013). Hemorrhage Risks, Patient Perspectives, and Quality-of-Life Issues. In: Lip, G., Shantsila, E. (eds) Handbook of Oral Anticoagulation. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-96-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-96-8_4

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-58-6

  • Online ISBN: 978-1-908517-96-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation